Online inquiry

IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13551MR)

This product GTTS-WQ13551MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets GPI-APs gene. The antibody can be applied in Benign prostatic hyperplasia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Aeromonas hydrophila
RefSeq NM_000615.7; NM_001144822.2; NM_000591.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684; 965; 929
UniProt ID P13591; P19256; P08571
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13551MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9864MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ10479MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ992MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ7498MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ7362MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ5537MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ6000MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ2054MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AH-PD1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW